EHA 2025: Hematology Advances & Challenges – Ola Landgren
Ola Landgren, MD, PhD, illuminates vital advances in multiple myeloma treatment and research at the EHA Congress 2025. His presentation spotlights the ADVANCE clinical trial and the integration of cutting-edge immunotherapies, aiming to reshape treatment strategies. Landgren, a leading expert, discusses the significant strides made in hematologic oncology, especially in extending overall survival rates and enhancing the quality of life for those with multiple myeloma. He emphasizes the ongoing challenges, particularly in finding a cure and developing targeted therapies for high-risk multiple myeloma patients. The focus remains on chemotherapy-free regimens and MOD-guided treatments. Learn how News Directory 3 keeps you informed about critical developments. Discover what’s next for revolutionary treatments and patient care.
Ola Landgren Highlights Myeloma Advances at EHA Congress 2025
Updated June 08, 2025
Ola Landgren, MD, PhD, from the sylvester Comprehensive Cancer Centre at the University of Miami, is set to share his insights on the latest developments in multiple myeloma at the European Hematology Association (EHA) Congress in Milan. Landgren’s presentation, scheduled for June 15, will cover the ADVANCE clinical trial, a study of carfilzomib, lenalidomide, and dexamethasone (KRD) with or without daratumumab for newly diagnosed multiple myeloma (NDMM) patients.
Landgren, a leading expert in multiple myeloma, expressed enthusiasm for the EHA 2025 Congress, particularly regarding advancements in both newly diagnosed and relapsed multiple myeloma treatment. he is especially interested in the integration of new immunotherapies and chemotherapy-free regimens in frontline and relapse settings. The potential of MOD (mitozantrone, vincristine, and dexamethasone) to guide treatment strategies and improve patient outcomes is another area of keen interest.
Reflecting on the past three decades,coinciding with the EHA Congress’s 30th anniversary,Landgren noted the significant progress in hematologic oncology.He recalled a time when multiple myeloma was considered a disease with limited treatment options. Today, with collaborative efforts worldwide, overall survival rates have dramatically improved, with some patients living 10 to 20 years or more. Landgren emphasized that many patients diagnosed around age 70 can now expect a lifespan comparable to individuals without the disease, thanks to new therapies for multiple myeloma.
despite these advancements in multiple myeloma, Landgren stressed the ongoing challenges. A primary focus remains finding a cure for the disease. Addressing the needs of patients with aggressive, high-risk disease biology is another critical area. Landgren advocates for further research to understand the biology of these high-risk subsets and develop more targeted therapies.He also highlighted the importance of chemotherapy-free regimens and MOD-guided treatments to enhance both survival and quality of life for patients.
There are a lot of trials that are looking to delay old school chemotherapy,like transplants and other chemotherapies,and how MOD can really help and improve patient outcomes and quality of life. I think there are a lot of changes to come, and I’m really vrey excited about the meeting.
What’s next
Looking ahead,Landgren aims to continue research into curative treatments for multiple myeloma and improved strategies for managing high-risk disease,ultimately striving to enhance patient outcomes and quality of life.